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Abstract
Background: The recommended strategy for elimination of Lymphatic filariasis is single-dose,
once-yearly mass treatment with anti-filarial drugs and the program is in operation on a national
level in India. Rate of coverage and consumption is the most crucial factor in the success of Mass
Drug Administration (MDA) program. In spite of massive efforts, the program demonstrated sub-
optimal coverage and consumption in urban areas than rural. The involvement of Anganwadi
workers (AWWs) of the Integrated Child Development Scheme (ICDS) as communicators and
drug distributors was attempted to enhance the coverage and consumption in urban areas and the
results presented here.
Methods: An annual single dose MDA program was launched under the auspices of Freedom From
Filariasis (FFF) program in Pondicherry, India, in the year 1997 and continued for five years. A
questionnaire survey was carried out following all the treatment rounds (TRs) for assessing
coverage of distribution and consumption Five percent of randomly selected households
constituted the sample. All the members available in the selected household at the time of interview
formed the respondent of the study.
Results: The coverage of drug distribution during the TRs varied from 74.3 to 95.4 percent and
consumption rate from 52.9 to 78.8. Among the respondents, 71% were aware of the MDA
program and the source of information for 62.8% of them was through personal communication
by the AWW. It was observed that 33.2% of the respondents who accepted the drug did so based
on the trust on the AWW as a government representative. The main reason for non-consumption
in all TRs was fear of side reaction (25.4 – 42.2%).
Conclusion: The delivery-strategy of health information and Diethylcarbamazine (DEC) drug to
the urban community using the AWWs could achieve relatively higher coverage and consumption
than reported in other urban areas. In order to achieve the optimum level, it is imperative to equip
the AWWs with current knowledge and skills, and design innovative Information, Education and
Communication (IEC) campaign to target the less compliant groups. The beneficial effect of this
delivery strategy may be used in similar urban settings to achieve the elimination of LF.
Published: 24 August 2007
Filaria Journal 2007, 6:7 doi:10.1186/1475-2883-6-7
Received: 14 August 2006
Accepted: 24 August 2007
This article is available from: http://www.filariajournal.com/content/6/1/7
© 2007 Nandha et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Filaria Journal 2007, 6:7 http://www.filariajournal.com/content/6/1/7
Page 2 of 6
(page number not for citation purposes)
Background
World wide 1.3 billion people are at risk of lymphatic
filariasis (LF) infection and about 120 million people are
affected in 83 countries [1]. Following the World Health
Assembly resolution (WHA 50.29) on Elimination of LF
as a public health problem by the year 2020, a global pro-
gram (GPELF) was launched in 1999 to help endemic
countries initiate national programs [2,3]. The global
strategy to interrupt transmission of LF, is a once-yearly,
single-dose, two-drug regimen (Albendazole with either
Diethylcarbamazine (DEC) or Ivermectin) to be used by
communities at risk with the goal of reaching 80% cover-
age for 4–6 years [4,5]. LF is an important public health
problem in India where about 553.7 million people are at
risk of infection in 243 districts [1], 29 million are parasite
carriers and 22 million are with chronic disease, account-
ing for 40% of the global burden [6,7]. In accordance with
global efforts several steps have been initiated towards
elimination of LF in India and Mass Drug Administration
(MDA) with DEC single dose is one of them. MDA with
DEC was launched as a pilot project in 13 districts of 7
states in the year 1996 [8]. Subsequently, it has been
expanded to target all endemic districts with introduction
of albendazole in selected districts. The MDA campaign in
2005 covered a population of 463 million using DEC
alone and 17.34 million with DEC plus albendazole com-
bination [1]. A large scale trial on the feasibility and
impact of co-administration of DEC plus albendazole in
selected districts in the country was carried out during the
year 2000 to 2005. The Indian Council of Medical
Research (ICMR) Task Force has recommended this co-
administration (DEC 6 mg/kg and albendazole 400 mg)
strategy to all endemic districts and the government
approval is awaited.
Previous studies have shown that urban areas recorded
lower rates of coverage and compliance than rural areas
[9,10]. Predictions indicate that at least 90% consump-
tion is required to achieve the goal of elimination with
five rounds of annual DEC based MDA and 11 rounds are
required if the coverage is 60% [11]. Two important com-
ponents in the MDA program are the delivery strategy of
the drug for wider coverage and the communication strat-
egy for compliance with the drug. In the year 1997 an
annual single dose DEC mass treatment program was
introduced under the auspices of Freedom From Filariasis
(FFF) program in the urban endemic areas of Pondicherry
and continued for five years. To achieve good coverage
and consumption, Anganwadi workers (AWWs) of the
Integrated Child Development Scheme (ICDS) who are
close associates of the community were involved in plan-
ning and implementation of MDA and the program was
evaluated independently. This paper reports the coverage
of distribution and consumption of the drug in five
rounds of annual single dose DEC administration in the
urban areas of Pondicherry involving AWWs as motiva-
tors and drug distributors.
Methods
Study area
The study was conducted in Muthialpet zone of Pon-
dicherry, South India, with a population of 47446, com-
prising of 8 administrative units or wards over a 9 sq km
area. The population in these wards ranges from 4130 to
7438. Over-population, migration and unplanned con-
struction in this zone have led to the creation of mosquito
breeding sources. The area is endemic for filariasis with an
infection rate of 3.82 in the year 1997 (VCRC Annual
report, 1998) and has been under selective chemotherapy
and routine vector control (anti-larval) operations. The
health care facilities in this area include a Government
General Hospital, a medical College hospital and many
private clinics. Mass anti-filarial drugs were not adminis-
tered to the study community prior to the implementa-
tion of MDA with DEC.
Implementation strategy
Mass DEC distribution began in 1997 based on a house-
to-house approach involving the AWWs. The job require-
ments of this female community health worker includes
supplementary nutrition, immunization, health check
ups, referral services, treatment of minor illness, nutrition
and health education for women, preschool education for
children aged 3–6 years, co-operation in improving sup-
portive services such as water supply and sanitation and
integrated services. An AWW is deputed for a population
of 500 – 1000. They have frequent contact with the people
in their respective areas and have gained acceptance as
caretakers of the community. We utilized this strong com-
munity based resource as an existing, established infra-
structure in the field of public health for popularizing the
program and involving the community in the mass DEC
program. Prior to each round of drug distribution, orien-
tation and training sessions were conducted for the 69
AWWs who were involved in the MDA program. The main
focus was on the disease cause, transmission, prevention
and the necessity for mass annual DEC administration
and methods and conditions of delivering the drug with
possible side reactions and management. The AWWs in
turn educated the community through interpersonal com-
munication techniques during enumeration of eligible
population prior to drug distribution. The feed back from
the AWWs was received after every round and the program
was modified accordingly. Campaigns through television,
radio, newspaper, banner, pamphlets and posters were
also conducted in a small scale. Door to door distribution
of the drug was carried out with in a period of one week
using a family enumeration register. Based on the require-
ment of each family, the DEC tablets were packed in sep-
arate covers and delivered to all the households. In case ofFilaria Journal 2007, 6:7 http://www.filariajournal.com/content/6/1/7
Page 3 of 6
(page number not for citation purposes)
absentees, the drug was left with available family member
or neighbor. Children below two years, pregnant ladies
and people under medication for chronic diseases were
exempted from drug administration. A standard dose of
DEC was worked out based on age, which corresponds to
6-mg/kg-body weight.
Design of the study
Assuming that the expected consumption rate will be with
in 60 ± 3%, with 95% confidence the minimum required
sample size was arrived at 1100 respondents and the cor-
responding percent of population was 2.5%. Hence, 5%
of the total households in the study area were selected
using simple random technique. All the members in the
selected household and available at home at the time of
interview formed the respondent of the study. The pur-
pose of research was communicated to the selected house-
hold members and their oral informed consent was
obtained before administering the questionnaire. They
were assured of confidentiality and anonymity.
The assessment in this study was made in terms of propor-
tion of people who have actually received DEC tablets (=
coverage of drug distribution), those who have consumed
the tablet (= consumption of tablet out of sampled popu-
lation) and compliance (= consumption of tablet out of
those received tablets) in the selected areas. A household
questionnaire survey was carried out with in fifteen days
of drug distribution following all the treatment rounds
(TRs), for assessing the coverage of distribution and con-
sumption. A semi-structured questionnaire in the local
language (Tamil) was used to collect information on cov-
erage, consumption and side effects of the drug, family
details of drug consumption, community's perception of
drug distribution, etc. People were also asked about the
channel through which they came to know about the drug
distribution and which communication method had
influenced them. During the final TR information was
also collected about the number of times the respondents
had received and consumed the drug during the previous
rounds.
Database was organized using excel spreadsheet and data
cleaning was carried out by verifying any inconsistency
against the original questionnaire. Analysis of data was
done using SPSS version.13. Mantel-Haenszel proportion
test was carried out for significance.
Results
Feedback from AWWs
According to the feedback from AWWs the average
number of households covered by a single worker in a day
was 49 ± 32 and the number of individuals given tablets
was 168 ± 105. To distribute the drugs, the average time
taken was 5 ± 2 days with 3 ± 1 hours per day by each
worker. Except a single case admitted in the hospital dur-
ing the first round for giddiness, no other serious side
reactions were reported to them. Those with mild to mod-
erate side reactions were referred to the nearest Primary
Health Centre. Majority of the AWWs (78.3%) felt that for
achieving high consumption rate, drug distribution
should be preceded by a strong Information, Education
and Communication (IEC) through different media.
Household survey
The total number of households visited and the total
number of individuals interviewed after the treatment
rounds (From 1997 to 2001) ranged from 263 to 689 and
1179 to 3195 respectively (Table 1). The same households
could not be followed up during the entire period under
study owing to the migratory nature of the urban popula-
tion. Assessments made based on the residential status of
the people showed that the residents in two of the 8 wards
belonged to high income group and the rest of the wards
had middle and lower income groups.
Coverage of DEC distribution and compliance
In all the TRs, the 8 wards included in the study had
received DEC tablets and the proportion of respondents
who had received the drug varied from 74.3 to 95.4%.
Between the wards, estimates of mean coverage of individ-
uals during the TRs varied from 45.9 to 95.0 percent. It
was observed that the percentage of respondents who had
directly received treatment from the drug distributors
ranged from 20.7 to 44.4% during the TRs and was lowest
in the fifth TR. A significantly higher (p =< 0.05) propor-
tion of females (76.06%) received the drug in the fifth TR
than males (67.28%) and no difference was observed in
the other rounds.
The average consumption rate for the study period was
66.1%. However the consumption rate varied in different
TRs, showing a high rate of 78.8 in TR 3 and a low rate of
52.9 in TR 5 (Figure 1). Ward to ward variation was also
observed, the consumption rate ranging from 37.1% to
92.0%. The variation seen in coverage of drug distribution
and consumption was significantly different among dif-
Table 1: Coverage of distribution and compliance of annual single 
dose DEC in Pondicherry during five consecutive rounds
Rounds
Item TR 1 TR 2 TR 3 TR 4 TR 5
Sample 1179 3195 2976 3127 1953
No. received drug 1020 2373 2791 2983 1519
% received 86.5 74.3 93.8 95.4 77.8
No. consumed drug 850 1947 2346 2040 1034
% consumed 72.1 60.9 78.8 65.2 52.9
Compliance rate 83.3 82.0 84.1 68.4 68.1Filaria Journal 2007, 6:7 http://www.filariajournal.com/content/6/1/7
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ferent rounds and wards. However, with in the same TR,
the relation between coverage and consumption was not
found to be significant (R2 = 0.0055; Y = 0.0539x +
74.288). Treatment coverage and consumption was found
to be lower in the two wards with high-income group res-
idents in all TRs, being statistically significant in TR4 and
TR5 (p =< 0.05).
The community compliance rate ranged from 68.1 to
83.3% in different TRs and 46.7 to 95.8% in different
wards. The rate of supervised consumption among the TRs
was in the range of 1.66 – 9.93%. The proportion of peo-
ple who received the drug but did not consume ranged
from 13.3 to 30.2% (Figure 1) in different TRs. The main
reason for non-compliance in all TRs was fear of side reac-
tion (25.4 – 42.2%). As many as 16.2 – 21.3% of respond-
ents did not feel the necessity to adhere to treatment since
they do not have disease symptoms and 15.6 – 21.2%
were undergoing treatment for other ailments (Table 2).
The low compliance rate in TR 4 was due to a death attrib-
uted to drug consumption in TR 4. Among those who con-
sumed the drug, it was observed that the trust on the
AWW as a government representative was the motive for
33.2% of the respondents and the fear of getting filariasis
impelled 29.3% to consume. About 22% consumed as
they were aware of its beneficial effect of the drug and
15.6% could not attribute any reason. Treatment compli-
ance was observed to be significantly (p =< 0.05) lower in
elderly respondents >61 years of age. Of those who were
interviewed during the final treatment round 8.5% had
consumed the drug in all the treatment rounds, while
23.2% had never complied with the treatment since the
inception of the FFF program. Compliance with 2 rounds
was the highest (32.2%) followed by three rounds
(16.5%). Undergoing treatment for some ailment was the
major reason for systematic non compliance. The propor-
tion of males (47.6%) who did not consume the drug in
any of the TRs was significantly (p =< 0.05) higher than
that of females (20.3%). A significantly (p =< 0.05) higher
proportion of females (10.3%) adhered to all the rounds
of treatment than males (2.9%).
The rate of adverse reactions observed ranged from 0.6 to
7.6% in different TRs, lowest being in TR 5 and highest in
TR 1. This difference was statistically significant (p =<
0.05). Fever, headache and dizziness were the common
adverse reactions reported. The average duration of any
side reaction was half a day and did not prevent the
respondents from carrying out their normal routine work.
About 71% of the respondents were aware of the drug dis-
tribution program. Personal communication by the AWW
was the source of information for 62.8% of them. A total
of 59.2% preferred to receive information on other health
matters also through the AWWs. Other sources of infor-
mation were advertisements in Television, Radio, news
papers, banners, pamphlets and posters. Having seen Tel-
evision advertisements was mentioned considerably more
Table 2: Reason for not consuming DEC tablets among those received in different rounds of treatment
Reasons TR 1
n = 170
TR 2
n = 426
TR 3
n = 445
TR 4
n = 943
TR 5
n = 485
No % No % No % No % No %
Aged 12 7.1 13 3.1 11 2.5 21 2.2 15 3.1
Sick/under treatment 36 21.2 79 18.5 70 15.7 147 15.6 103 21.2
Pregnant and lactating 13 7.6 22 5.2 35 7.9 38 4.0 17 3.5
Fear of side reaction 47 27.6 120 28.2 133 29.9 398 42.2 123 25.4
Forgot 22 12.9 65 15.3 87 19.6 99 10.5 84 17.3
No disease/not willing 30 17.6 88 20.7 95 21.3 153 16.2 102 21.0
Out of station 10 5.9 39 9.2 14 3.1 87 9.2 41 8.5
Coverage of DEC drug distribution and consumption in dif- ferent rounds of treatment Figure 1
Coverage of DEC drug distribution and consumption in dif-
ferent rounds of treatment.Filaria Journal 2007, 6:7 http://www.filariajournal.com/content/6/1/7
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often by the women folk (27.6%) than men. Those who
received information through print media was very low
(7.7%) and was found to be gender dependent (59.3%
men compared to 31.2% of women).
Discussion
Massive efforts have been taken by the national and state
governments along with World Health Organization
(WHO), towards elimination of LF in India as a public
health problem. In a country like India, annual MDA is an
economic option [12] and the existing health care system
is capable of operating the program [9,10]. However stud-
ies have shown that the main limitation in this program is
a comparatively poor coverage of drug distribution and
consumption in urban areas [9,10]. The rate of coverage
and consumption is the most crucial factor in the success
of MDA program and this is to a large extent dependant
on the type of personnel involved in drug distribution.
Programs based on community health workers have been
successfully employed to address several health problems
throughout the world [13-15]. The present study has dem-
onstrated the role of AWWs in achieving more than 70%
coverage of DEC drug distribution and more than 68%
compliance in all the five TRs in urban areas. This is higher
than the coverage of 53% [9] and 44.9% [10] and compli-
ance of 35% [9] and 23.1% [10] reported earlier in Tamil
Nadu and Orissa, India respectively. Due to periodic con-
tact with the community members, the AWWs have
earned the trust of their respective communities. This
could be a significant contributory factor for the higher
rate of coverage and consumption observed in the study.
Enhanced compliance could have a major impact on the
number of annual rounds of MDA required to achieve
elimination. However, the coverage and consumption
was significantly different in various TRs and between
wards. The migratory nature of the population in urban
areas is perhaps the reason for the difference observed.
Fear of side reaction was the most common cause for non
consumption of the drug. A high rate of side reaction in
TR 1 affected the acceptance rate in TR 2. Following ade-
quate mobilization with health education messages the
acceptance rate went up again in TR 3. In different rounds
of MDA 17.6–21.3% of the respondents did not adhere to
treatment, due to the reason that they do not have disease
symptoms or manifestation. One way of interpreting this
is that side reactions and need for apparently healthy peo-
ple to consume the tablets are not accepted by the com-
munity. This is suggestive of a low health literacy of the
community, a factor that can have significant bearing on
the individual's ability to comprehend the necessity of
preventive care utilization [16]. Another reason for low
awareness is inadequate publicity through media. To
tackle the problem of systematic non-compliance
reported during the final TR, it is essential to deliver
appropriate health information designed specifically to
address people's concerns and fears about the interven-
tion.
The percentage of coverage and consumption was found
to decline with increasing age as observed in another
study [17]. Income level seemed to play an independent
significant role, compliance being lowest among the high-
income group. Feed back from the AWWs revealed that
entering the premises of residents in high-income areas
for drug distribution itself was difficult as the entrances
were locked most of the time, and wherever entry was pos-
sible the response was poor. These people were not will-
ing to take preventive medication and this could perhaps
be due to the fact that for such people preventive medica-
tion is not a felt need as they could afford treatment from
health facilities of their choice.
Throughout the study period, we depended on the AWWs
for dissemination of information and it is evident from
the findings that the message on DEC drug distribution
had percolated into the community. But, the achieved
coverage and consumption levels are not sufficient to
completely interrupt transmission and low-level disease
transmission and occurrence of new infections would
continue. Therefore, from the elimination point of view,
there is a need to enhance the existing levels of compli-
ance with the AWWs as drug distributors. To achieve this,
the enthusiasm of the AWWs should be maintained by
motivational activities and they should be equipped with
necessary knowledge and skills through effective re-train-
ing to target less compliant groups. Even though we
attempted IEC through electronic and print media on a
small scale, the results indicate that it was not adequate.
Further efforts are necessary to harness the interests of tar-
get communities in order to enable passive beneficiaries
to modify their behavior and change mind sets and trans-
form into active accountable stakeholders in the MDA
program. It is therefore imperative to have an innovative
IEC that is appropriate to the local environment, health
system, social structure, culture, population density and
method of drug distribution[2]. Urban areas may benefit
from education through social organizations such as
neighborhood associations, housing associations, youth
organizations etc. that foster social capital.
Conclusion
This study shows that the strategy adopted for MDA in
urban areas using AWWs has achieved enhanced coverage
and consumption. Two conclusions can be drawn from
the results obtained in this study. Firstly, MDA to urban
population utilizing the services of AWWs as motivators
and drug distributors is operationally feasible. Secondly,
even though the improved coverage and consumption
achieved are not sufficient to completely interrupt trans-
mission, the levels have reached a stage which can be fur-Publish with BioMed Central    and   every 
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ther enhanced to optimum levels with adequate
mobilization through innovative IEC campaigns. This
will pave way to our efforts to achieve the goal of elimina-
tion of LF as a public health problem.
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